Results
|
|
1.
|
Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. MedStar authors:
Year: 2016
Citation: - Journal of Clinical Endocrinology & Metabolism. 101(4):1754-61, 2016 Apr
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
All authors: - Aroda VR, Bray GA, Crandall JP, Diabetes Prevention Program Research Group, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, Schade DS, Temprosa MG, White NH
|
|
|
2.
|
Genetic risk of progression to type 2 diabetes and response to intensive lifestyle or metformin in prediabetic women with and without a history of gestational diabetes mellitus. MedStar authors:
Year: 2014
Citation: - Diabetes Care. 37(4):909-11, 2014 Apr.
Institution: - MedStar Washington Hospital Center
Medline publication type:
- Journal Article
- Research Support, N.I.H., Extramural
All authors: - Christophi CA, Dabelea D, Dagogo-Jack S, Diabetes Prevention Program Research Group, Florez JC, Franks PW, Jablonski KA, Kim C, Knowler WC, Ratner R, Sullivan SD
|
|
|
3.
|
Metformin Attenuates 131I-Induced Decrease in Peripheral Blood Cells in Patients with Differentiated Thyroid Cancer. MedStar authors:
- Bikas, Athanasios
- Burman, Kenneth D
- Desale, Sameer
- Mete, Mihriye
- Van Nostrand, Douglas
- Wartofsky, Leonard
Year: 2016
Citation: - Thyroid. 26(2):280-6, 2016 Feb
Institution:
- MedStar Health Research Institute
- MedStar Heart & Vascular Institute
- MedStar Washington Hospital Center
Department:
- Medicine/Endocrinology
- Medicine/Nuclear Medicine
Medline publication type:
All authors: - Bikas A, Burman KD, Desale S, Jensen K, Mete M, Patel A, Van Nostrand D, Vasko V, Wartofsky L
|
|
|
4.
|
|
|
|
5.
|
Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer. MedStar authors:
- Burman, Kenneth D
- Klubo-Gwiezdzinska, Joanna
- Mete, Mihriye
- Wartofsky, Leonard
Citation: - Journal of Clinical Endocrinology & Metabolism. 98(8):3269-79, 2013 Aug.
Institution:
- MedStar Health Research Institute
- MedStar Washington Hospital Center
Medline publication type:
- Journal Article
- Research Support, Non-U.S. Gov't
All authors: - Bauer A, Burman KD, Costello J Jr, Jensen K, Klubo-Gwiezdzinska J, Mete M, Patel A, Vasko V, Wartofsky L
|
|
|
6.
|
Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). MedStar authors:
Year: 2014
Citation: - Journal of Diabetes & its Complications. 28(3):386-92, 2014 May-Jun.
Institution: - MedStar Health Research Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Boka G, Hanefeld M, Min KW, Miossec P, Muehlen-Bartmer I, Ratner RE, Rosenstock J, Shamanna P, Zhou T
|
|
|
7.
|
Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS). MedStar authors:
Year: 2017
Citation: - Diabetic Medicine. 34(12):1747-1755, 2017 Dec.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Barrett-Connor E, Dabelea D, Dagogo-Jack S, Hamman RF, Kahn SE, Knowler WC, Mather KJ, Pan Q, Perreault L, The Diabetes Prevention Program Research Group
|
